Yarrow Bioscience, Inc. (YARW)
41.70
+2.45
(+6.24%)
USD |
NASDAQ |
Aug 26, 10:56
Yarrow Bioscience Enterprise Value : 3.306M for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 3.306M |
| August 24, 2026 | 3.473M |
| August 21, 2026 | 1.418M |
| August 20, 2026 | 2.604M |
| August 19, 2026 | 4.208M |
| August 18, 2026 | 4.823M |
| August 17, 2026 | 4.743M |
| August 14, 2026 | 5.471M |
| August 13, 2026 | 5.625M |
| August 12, 2026 | 5.658M |
| August 11, 2026 | 5.772M |
| August 10, 2026 | 5.124M |
| August 07, 2026 | 4.763M |
| August 06, 2026 | 4.900M |
| August 05, 2026 | 2.270M |
| August 04, 2026 | 2.440M |
| August 03, 2026 | -0.4768M |
| July 31, 2026 | 0.4789M |
| July 30, 2026 | -0.8778M |
| July 29, 2026 | -2.575M |
| July 28, 2026 | -4.179M |
| July 27, 2026 | -3.838M |
| July 24, 2026 | -5.917M |
| July 23, 2026 | 7.930M |
| July 22, 2026 | 7.068M |
| Date | Value |
|---|---|
| July 21, 2026 | 6.905M |
| July 20, 2026 | 4.068M |
| July 17, 2026 | 2.504M |
| July 16, 2026 | 2.721M |
| July 15, 2026 | 2.377M |
| July 14, 2026 | 0.8331M |
| July 13, 2026 | -0.9413M |
| July 10, 2026 | -1.620M |
| July 09, 2026 | -0.4701M |
| July 08, 2026 | -1.199M |
| July 07, 2026 | -0.5436M |
| July 06, 2026 | -0.6171M |
| July 02, 2026 | -0.2061M |
| July 01, 2026 | -0.1694M |
| June 30, 2026 | -1.182M |
| June 29, 2026 | -3.331M |
| June 26, 2026 | -3.304M |
| June 25, 2026 | -3.190M |
| June 24, 2026 | -3.227M |
| June 23, 2026 | -3.247M |
| June 22, 2026 | -3.247M |
| June 18, 2026 | -3.734M |
| June 17, 2026 | -3.878M |
| June 16, 2026 | -3.818M |
| June 15, 2026 | -4.181M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Oramed Pharmaceuticals, Inc. | 165.37M |
| NRX Pharmaceuticals, Inc. | 132.95M |
| ANI Pharmaceuticals, Inc. | 1.972B |
| Corcept Therapeutics, Inc. | 13.04B |
| Veru, Inc. | 23.10M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.899M |
| Revenue (Quarterly) | 0.097M |
| Total Expenses (Quarterly) | 2.996M |
| EPS Diluted (Quarterly) | -3.504 |
| Gross Profit Margin (Quarterly) | 93.81% |
| Profit Margin (Quarterly) | -2.99K% |
| Earnings Yield | -56.25% |
| Normalized Earnings Yield | -56.25 |